tiprankstipranks
Advertisement
Advertisement
BioCryst reports inducement grants under Nasdaq listing rule
PremiumThe FlyBioCryst reports inducement grants under Nasdaq listing rule
2M ago
BioCryst price target raised to $22 from $21 at Wedbush
Premium
The Fly
BioCryst price target raised to $22 from $21 at Wedbush
2M ago
Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value
Premium
Company Announcements
Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value
2M ago
Is BCRX a Buy, Before Earnings?
PremiumPre-EarningsIs BCRX a Buy, Before Earnings?
2M ago
BioCryst resumed with an Outperform at Evercore ISI
Premium
The Fly
BioCryst resumed with an Outperform at Evercore ISI
2M ago
BioCryst reports inducement grants under Nasdaq listing rule
Premium
The Fly
BioCryst reports inducement grants under Nasdaq listing rule
3M ago
BioCryst Updates ORLADEYO Revenue Outlook and Guidance
PremiumCompany AnnouncementsBioCryst Updates ORLADEYO Revenue Outlook and Guidance
4M ago
BioCryst reports preliminary Q4 ORLADEYO revenue $151M
Premium
The Fly
BioCryst reports preliminary Q4 ORLADEYO revenue $151M
4M ago
BioCryst sees FY26 revenue $635M-$660M
Premium
The Fly
BioCryst sees FY26 revenue $635M-$660M
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100